Leaders in Life Sciences

Leaders in Life Sciences

By Dr. Kesha Chauhan, MDNewsScienceMedicineHealth & FitnessBusiness NewsLife Sciences
Download on the App Store

Leaders in Life Sciences episodes

  • 29: Another Recall for Glenmark: Millions of Bottles of Generic ADHD Drug Pulled
    Glenmark Pharmaceuticals has recalled nearly 1.5 million bottles of generic atomoxetine (ADHD medication) due to unacceptable levels of a potential carcinogen, N-nitroso atomoxetine. This recall, from January 2024, adds to a series of recent recalls by Glenmark, including potassium chloride capsules (June 2024), diltiazem hydrochloride (December 2024), and various other drugs in 2023 and 2022, due to manufacturing and impurity issues. These repeated recalls raise concerns about Glenmark's quality control, and patients taking Glenmark's atomoxetine are advised to consult their healthcare providers.

    Hosted on Acast. See acast.com/privacy for more information.

    6 min
  • 28: Novo Nordisk's Bold Leap into Rare Diseases
    Novo Nordisk is strategically expanding into rare diseases, shifting from its traditional focus on common chronic conditions, by significantly increasing R&D investment and executing key acquisitions to build a strong portfolio in blood, endocrine, and hemato-renal disorders. The company aims to achieve long-term leadership in this space through internal innovation, strategic partnerships, and further mergers and acquisitions.

    Hosted on Acast. See acast.com/privacy for more information.

    10 min
  • 27: FDA Updates Labeling and Safety Information For Testosterone Products

    The FDA is updating the labeling for all FDA-approved testosterone products (oral, topical gel, transdermal patch, buccal system, and injection) based on the TRAVERSE trial and ABPM studies. The results of the TRAVERSE trial are being added to all testosterone product labels, and the language in the Boxed Warning related to an increased risk of adverse cardiovascular outcomes will be removed from all testosterone products. The TRAVERSE trial found no increased risk of adverse cardiovascular outcomes in men using testosterone for hypogonadism.

    However, the "Limitation of Use" language for age-related hypogonadism is being retained. A new warning about increased blood pressure is being added to products without such a warning. Furthermore, product-specific information on increased blood pressure will be included for products with completed ABPM studies. ABPM studies confirmed an increase in blood pressure with the use of all testosterone products. These actions follow prior FDA warnings about the risks of stroke, heart attack, and death in men taking testosterone products. Testosterone is only approved for use in men with low testosterone levels in conjunction with an associated medical condition.

    Hosted on Acast. See acast.com/privacy for more information.

    7 min
  • #22: Point-of-Care Messaging and Boosted Vaccine Uptake
    A study by Phreesia demonstrated that point-of-care messaging significantly increases vaccine uptake. Patients who received vaccine information prior to their appointments were more than twice as likely to get vaccinated compared to a control group. The study, which ran from March 2020 to May 2024, also found that many patients found the information new and were more likely to discuss vaccines with their doctor. This approach could help counteract declining vaccine confidence and improve vaccination rates.

    Hosted on Acast. See acast.com/privacy for more information.

    6 min
  • #26: Moderna Faces Manufacturing Costs and Revenue Challenges
    In 2024, Moderna faced financial challenges including $739 million in cost of sales for the fourth quarter, which factored in $193 million in inventory write-downs, $259 million in production wind-down costs, and a $238 million charge from a cancelled contract. The company's total revenue for 2024 was $3.2 billion, a 72% decrease from the previous year. Moderna is working to resize its production footprint to meet post-pandemic needs and has struggled to accurately gauge vaccine demand in the current market. Moderna anticipates revenue between $1.5 billion and $2.5 billion in 2025.

    Hosted on Acast. See acast.com/privacy for more information.

    6 min
  • #24: US Pharma and Life Sciences Deals: 2025

    The pharmaceutical and life sciences sector anticipates a surge in merger and acquisition activity in 2025. Driving this trend are expected interest rate reductions by the Federal Reserve and the resolution of post-election uncertainties. While deal values and volumes are projected to rise, transactions in the $5 billion to $15 billion range are forecasted to be the most common. However, geopolitical issues could present obstacles to this growth.




    Hosted on Acast. See acast.com/privacy for more information.

    14 min
  • #22: Glatiramer Acetate : Anaphylaxis Risk and Warnings

    The FDA is alerting the public to the risk of anaphylaxis, a rare but serious allergic reaction, associated with glatiramer acetate (Copaxone, Glatopa), a drug used to treat multiple sclerosis (MS). Anaphylaxis can occur at any time during treatment, even after doses administered months or years after starting the medicine, and has sometimes resulted in hospitalization and death. Symptoms typically appear within one hour of injection.

    To communicate this risk, the FDA is adding a Boxed Warning to the prescribing information and patient Medication Guide. Patients should stop taking glatiramer acetate and seek immediate medical attention if they experience symptoms of anaphylaxis such as wheezing, difficulty breathing, swelling of the face, lips, or throat, or hives. While early symptoms of anaphylaxis can be similar to a temporary post-injection reaction, they are typically more severe and worsen over time. If symptoms are more than mild, worsen, or do not go away quickly, patients should seek immediate medical attention

    Hosted on Acast. See acast.com/privacy for more information.

    5 min
  • #22: Novo Nordisk's next gen weight loss drug
    Novo Nordisk, known for its obesity drugs Ozempic and Wegovy, reported strong profit and revenue for 2024, surpassing Wall Street expectations. However, the company expects slower sales growth in 2025 due to rising competition, particularly from Eli Lilly, and pricing pressures. Despite this, Novo Nordisk remains optimistic, citing continued strong demand for obesity treatments and its drug pipeline, including CagriSema and amycretin. The company’s stock experienced volatility, partly due to concerns about obesity drug demand and geopolitical factors like tariffs. While uncertain about global trade impacts, Novo Nordisk is confident in the long-term potential of its drugs.

    Hosted on Acast. See acast.com/privacy for more information.

    13 min

About Leaders in Life Sciences

From the publisher's feed

The Leaders in Life Sciences podcast features daily news, strategies, interviews with healthcare professionals, and life science executives. This show is for commercial and medical leaders who want to…